| Lead Manager/ | # of | Price Range | Dollar | SCOOP | ||
| New Filings (Proposed Symbol) | Joint-Lead Managers | Shares | Low | High | Volume | Ratings |
| Colony Global Acquisition (CCACU) (u) | Credit Suisse | 30.00 | $10.00 | $10.00 | $300.00 | n.a. |
| n.a. (not available) | ||||||
| u (unit offering) | ||||||
| Postponed | ||||||
| PLx Pharma (PLXP) | Raymond James/ Maxim Group LLC | 3.80 | $17.00 | $19.00 | $68.40 | 1-Star |
| Withdrawn | ||||||
| Petco Holdings (TBA) | Goldman Sachs/ BofA Merrill Lynch/ J.P. Morgan | $100.00 | n.a. | |||
| New Terms | ||||||
| Advanced Disposal Services (ADSW) | Deutsche Bank Securities/ Credit Suisse/ Barclays | 21.43 | $20.00 | $22.00 | $450.00 | 1-Star |
| AveXis (AVXS) | Goldman Sachs/ Jefferies | 4.25 | $19.00 | $21.00 | $85.00 | 1-Star |
| Cancer Prevention Pharmaceuticals (CPP) | Aegis Capital/ Maxim Group | 1.92 | $12.00 | $14.00 | $25.00 | 1-Star |
| Proteostasis Therapeutics (PTI) | Leerink Partners/ BC Capital Markets | 3.85 | $12.00 | $14.00 | $50.05 | 1-Star |
| IPOs Priced | Lead | Shares | Amount | Offer | Close | % |
| Week of Feb. 1, 2016 | Manager(s) | Offered | Raised | Price | 2/5/16 | Change |
| BeiGene, Ltd. (BGNE) | Goldman Sachs/ Morgan Stanley/ Cowen and Company | 6.60 | $158.40 | $24.00 | $33.91 | 41.29% |
| Editas Medicine (EDIT) | Morgan Stanley/ J.P. Morgan | 5.90 | $94.40 | $16.00 | $17.60 | 10.00% |
